-
Sanara MedTech reports revenue growth, provides 2026 guidance
-
Sanara MedTech receives innovative technology contract from Vizient
-
Sanara MedTech plans US launch of bone adhesive product in Q1 2027
-
Sanara MedTech discontinues Tissue Health Plus to focus on surgical unit
-
Sanara MedTech (SMTI) PT Raised to $54 at H.C. Wainwright
-
Cantor Fitzgerald Reiterates Overweight Rating on Sanara MedTech (SMTI)
-
Sanara MedTech launches wound care provider pilot program
-
Cantor Fitzgerald Reiterates Overweight Rating on Sanara MedTech (SMTI)
-
Sanara MedTech (SMTI) PT Raised to $53 at H.C. Wainwright
-
Sanara MedTech Inc. (SMTI) Misses Q1 EPS by 14c
-
Cantor Fitzgerald Reiterates Overweight Rating on Sanara MedTech (SMTI)
-
Sanara MedTech (SMTI) PT Raised to $51 at H.C. Wainwright
-
Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
-
Sanara MedTech (SMTI) PT Raised to $46 at Cantor Fitzgerald
-
Sanara MedTech (SMTI) Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd
-
Sanara MedTech (SMTI) Expands Executive Leadership
-
H.C. Wainwright Starts Sanara MedTech (SMTI) at Buy
-
Sanara MedTech Inc. (SMTI) Tops Q3 EPS by 28c
-
Sanara MedTech (SMTI) Announces Board Changes
-
Sanara MedTech (SMTI) and InfuSystem Announce Exclusive United States Distribution Agreement with, and Minority Investment in, ChemoMouthpiece, LLC
-
Sanara MedTech Inc. (SMTI) Misses Q2 EPS by 20c

